An assessment of teicoplanin use and monitoring serum levels in a Chinese teaching hospital

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 1, 2011, Pages 14-22

  Dong, Y L ^a   Dong, H Y ^a   Hu, S S ^a   Wang, X ^a   Wei, Y X ^a   Wang, M Y ^a   Dong, W H ^a   Yao, H P ^a   You, H S ^a   Xing, J F ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

High performance liquid chromatography; Serum drug concentration; Teicoplanin; Therapeutic drug monitoring

Indexed keywords

ALBUMIN; CREATININE; TEICOPLANIN;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHEST INFECTION; CHINESE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG STABILITY; DRUG STORAGE; DRUG TREATMENT FAILURE; DRUG USE; ERADICATION THERAPY; FEASIBILITY STUDY; FEMALE; FREEZE THAWING; GRAM POSITIVE INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; LOADING DRUG DOSE; LUNG INFECTION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OUTCOME ASSESSMENT; PATIENT MONITORING; PERSISTENT INFECTION; REPRODUCIBILITY; TEACHING HOSPITAL; TREATMENT DURATION; UROGENITAL TRACT INFECTION; VALIDATION PROCESS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TEICOPLANIN;

EID: 78650831587     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201374     Document Type: Article

References (31)

1. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother. 1996; 37: 209-222.
2. Sanchez A, Lopez-Herce J, Cueto E et al. Teicoplanin pharmacokinetics in critically ill paediatric patients. J Antimicrob Chemother. 1999; 44: 407-409. (Pubitemid 29425696)
3. He LX, Pan J, Chen SY et al. Clinical study of teicoplanin in the treatment of patients with gram-positive cocci: the Chinese experience. Zhonghua Nei Ke Za Zhi. 2005; 44: 337-341.
4. Rose WE, Kaatz GW, Sakoulas G et al. Teicoplanin pharmacodynamics in reference to the accessory gene regulator (agr) in Staphylococcus aureus using an in vitro pharmacodynamic model. J Antimicrob Chemother. 2008; 61: 1099-1102.
5. Traczewski MM, Katz BD, Steenbergen JN et al. Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob Agents Chemother. 2009; 53: 1735-1738.
6. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000; 39: 167-183.
7. Dykhuizen RS, Harvey G, Stephenson N et al. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother. 1995; 39: 1842-1847.
8. Yano R, Nakamura T, Tsukamoto H et al. Variability in teicoplanin protein binding and its prediction using serum albumin concentrations. Ther Drug Monit. 2007; 29: 399-403.
9. Calain P, Krause KH, Vaudaux P et al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 1987; 155: 187-91.
10. Harding I, MacGowan AP, White LO et al. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother. 2000; 45: 835-841.
11. Sato M, Chida K, Suda T et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother. 2006; 12: 185-189.
12. Pea F, Brollo L, Viale P et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother. 2003; 51: 971-975.
13. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001; 52 (Suppl): 35-43.
14. Schaison G, Graninger W, Bouza E. Teicoplanin in the treatment of serious infection. J Chemother. 2000; 12 (Suppl): 26-33.
15. Reed MD, Yamashita TS, Myers CM et al. The pharmacokinetics of teicoplanin in infants and children. J Antimicrob Chemother. 1997; 39: 789-796.
16. McCann SJ, White LO, Keevil B. Assay of teicoplanin in serum: comparison of high-performance liquid chromatography and fluorescence polarization immunoassay. J Antimicrob Chemother. 2002; 50: 107-110. (Pubitemid 34785262)
17. Hamdan M, Curcuruto O, Di Modugno E. Investigation of complexes between some glycopeptide antibiotics and bacterial cell-wall analogues by electrospray and capillary zone electrophoresis/electrospray-mass spectrometry. Rapid Commun Mass Spectrom. 1995; 9: 883-887.
18. Cociglio M, Peyriere H, Hillaire-Buys D et al. Application of a standardized coextractive cleanup procedure to routine high-performance liquid chromatography assays of teicoplanin and ganciclovir in plasma. J Chromatogr B Biomed Sci Appl. 1998; 705: 79-85.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
20. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investig Drugs. 2006; 7: 740-749.
21. Daschner FD, Kropec A. Glycopeptides in the treatment of staphylococcal infections. Eur J Clin Microbiol Infect Dis. 1995; 14 (Suppl): 12-17.
22. Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 1999; 47: 23-30.
23. Bechtold M, Felinger A, Held M et al. Adsorption behavior of a teicoplanin aglycone bonded stationary phase under harsh overload conditions. J Chromatogr A. 2007; 1154: 277-286.
24. Mochizuki N, Ohno K, Shimamura T et al. Quantitative determination of individual teicoplanin components in human plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 847: 78-81.
25. Norton D, Crow B, Bishop M et al. High performance liquid chromatography-tandem mass spectrometry (HPLC/MS/MS) assay for chiral separation of lactic acid enantiomers in urine using a teicoplanin based stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 850: 190-198.
26. Schmid MG, Holbling M, Schnedlitz N et al. Enantioseparation of dipeptides and tripeptides by micro-HPLC comparing teicoplanin and teicoplanin aglycone as chiral selectors. J Biochem Biophys Methods. 2004; 61: 1-10.
27. McElrath MJ, Goldberg D, Neu HC. Allergic cross-reactivity of teicoplanin and vancomycin. Lancet. 1986; 1: 47.
28. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003; 9: 978-984.
29. Zetola N, Francis JS, Nuermberger EL et al. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005; 5: 275-286.
30. Cepeda J, Hayman S, Whitehouse T et al. Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit. J Antimicrob Chemother. 2003; 52: 533-534.
31. Beltrametti F, Consolandi A, Carrano L et al. Resistance to glycopeptide antibiotics in the teicoplanin producer is mediated by van gene homologue expression directing the synthesis of a modified cell wall peptidoglycan. Antimicrob Agents Chemother. 2007; 51: 1135-1141. (Pubitemid 46586785)